A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Enalapril and Hydrochlorothiazide (Vaseretic)

Enalapril and Hydrochlorothiazide reduces fluid retention and lowers blood pressure by increasing urine output.

First FDA approval1986-10-31
Generic availableYes · 2 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.154/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.157
Across all dosage forms in distribution.
Highest NADAC
$0.159
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Enalapril and Hydrochlorothiazide used for?

Enalapril and Hydrochlorothiazide reduces fluid retention and lowers blood pressure by increasing urine output.

Is there a generic for Enalapril and Hydrochlorothiazide?

Yes. 4 ANDAs filed at FDA, 2 generic manufacturers currently shipping.

How much does my plan pay for Enalapril and Hydrochlorothiazide?

Across 329 Part D plans, Enalapril and Hydrochlorothiazide averages $0.157/unit (NADAC). Lowest available: $0.154/unit. Highest in distribution: $0.159/unit.

Is Enalapril and Hydrochlorothiazide on the FDA shortage list?

No. Enalapril and Hydrochlorothiazide is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (6 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.